Tilray | TRLY - Assets


Tilray reported $2.1B in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Acasti Pharma USD 68.49M 1.91M Dec/2025
Akebia Therapeutics USD 362.52M 14.04M Mar/2026
Alaunos Therapeutics USD 1.88M 1.08M Mar/2026
Aurora Cannabis CAD 775.29M 18.43M Dec/2025
Avita Medical AUD 56.39M 1.74M Dec/2025
Canopy Growth CAD 1.11B 36.35M Dec/2025
Cronos Group USD 1.17B 25.03M Mar/2026
Dianthus Therapeutics USD 1.25B 715.96M Mar/2026
Divis Laboratories Ltd INR 200.33B 18.82B Mar/2026
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
IQVIA Holdings USD 29.68B 269M Mar/2026
Knight Therapeutics CAD 1.05B 2.28M Dec/2025
Moderna USD 11.49B 850M Mar/2026
Organigram Holdings CAD 530.67M 31.54M Dec/2025
Organon & Co USD 13B 129M Mar/2026
Revvity USD 12B 171.82M Mar/2026
Tectonic Therapeutic USD 246.58M 14.46M Mar/2026
Tilray USD 2.1B 15.95M Sep/2025
Viatris USD 36.83B 358.5M Mar/2026
Xeris Pharmaceuticals USD 392.01M 8.49M Mar/2026
Zealand Pharma A/S 15.95B 848.45M Dec/2025